Takeda To Join With Baxter Of U.S. To Produce Bird-Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and U.S.-based Baxter International have agreed to join in producing influenza vaccines, with a goal of having the first on the Japanese market in fiscal 2012. The agreement involves Takeda licensing Baxter's vaccine-production technology, which involves cell-culture-based production, considered faster and better suited for mass vaccine production. The initial vaccine envisioned is one to protect against the H5N1 bird flu virus, feared capable of becoming an epidemic. (Click here for more - a subscription may be required
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.